Abbvie ((ABBV)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AbbVie is conducting a Phase 3b clinical study titled A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab. The study aims to evaluate the safety and effectiveness of risankizumab versus vedolizumab in adults with moderate to severe ulcerative colitis who have not previously received targeted therapies. This research is significant as it could offer new insights into treatment options for this challenging condition.
The interventions being tested are risankizumab and vedolizumab, both of which are approved drugs for treating moderate to severe ulcerative colitis. Risankizumab is administered intravenously during the induction phase and subcutaneously during the maintenance phase, while vedolizumab is given intravenously throughout the study.
The study design is interventional with a randomized allocation and parallel intervention model. There is no masking, and the primary purpose is treatment. This straightforward design helps ensure clear comparisons between the two drugs.
The study began on June 17, 2025, with an estimated primary completion date yet to be announced. The last update was submitted on July 22, 2025. These dates are crucial as they guide investors on the study’s progress and potential timelines for results.
This study update could influence AbbVie’s stock performance by potentially enhancing its product portfolio if risankizumab proves more effective. It also positions AbbVie competitively in the ulcerative colitis treatment market, where innovation is key. Investors should monitor this study’s outcomes closely.
The study is currently recruiting, and further details are available on the ClinicalTrials portal.